

Incyte is a drug discovery and development company which hopes to build a proprietary product pipeline of novel small molecule drugs. Among its major competitors, Incyte is ranked in 2nd place for NPS while Karyopharm Therapeutics is 1st, and Biogen is 3rd.
Incyte's Net Promoter Score (NPS) is a 46 with 69% Promoters, 8% Passives, and 23% Detractors. Net Promoter Score tracks whether Incyte's customers would recommend using the product based on a scale of -100 to 100.
| 69% | Promoters |
|---|---|
| 8% | Passives |
| 23% | Detractors |
| Summary | Date | Score |
|---|---|---|
Mar 2022 100 | Mar 2022 | 100 |
Oct 2022 50 | Oct 2022 | 50 |
Nov 2022 66 | Nov 2022 | 66 |
Dec 2022 25 | Dec 2022 | 25 |
Apr 2023 40 | Apr 2023 | 40 |
Jan 2024 49 | Jan 2024 | 49 |
Feb 2024 29 | Feb 2024 | 29 |
May 2024 37 | May 2024 | 37 |
Aug 2024 44 | Aug 2024 | 44 |
Mar 2025 50 | Mar 2025 | 50 |
Jun 2025 36 | Jun 2025 | 36 |
Oct 2025 46 | Oct 2025 | 46 |
Incyte is ranked first for NPS among its competitors. Biogen and MyoKardia come in second and third, with Reata Pharmaceuticals coming in at #4.
![]() Incyte | ![]() Biogen | ![]() MyoKardia | ![]() Reata Pharmaceuticals | |
| Global Ranking | #- | #388 | #- | #- |
| NPS | 46 | 21 | - | - |
| Social Sentiment Calculated by analyzing social media and other online mentions | - | Neutral | Neutral | - |
| Valuation Updated every 24 hours for public companies | - | $42.46B | $11.99B | $2.95B |
Net Promoter Score (NPS) is a management tool that can be used to gauge the satisfaction of a firm's customer relationships. NPS has been widely adopted as a key metric often linked to the revenue potential of a company’s product or service. The metric is based on customer responses to the question: "On a scale of 0 to 10, how likely are you to recommend the product to a friend?"
Those who respond with a score of 9 to 10 are known as Promoters, and are widely associated with behaviors that create value, including actively encouraging others to use the product or service. Those who respond with a score of 7 or 8 are categorized as Passives, and they are believed to be less likely to exhibit the value-creation traits of Promoters having a largely neutral effect on other consumers. Detractors are those who fall in the score range of 0 to 6 and represent dissatisfied customers of the product sometimes actively recommending against using the product.
Compared to its competitors, Incyte's NPS is rated right above Biogen, and is preceded by Karyopharm Therapeutics.
| COMPANY | NPS Score | |
|---|---|---|
![]() | Karyopharm Therapeutics | 100 |
![]() | Incyte | 46 |
![]() | Biogen | 21 |
![]() | ARIAD Pharmaceuticals | N/A |
![]() | MyoKardia | N/A |
![]() | Reata Pharmaceuticals | N/A |
![]() | Pharmacyclics | -100 |
![]() | National Research Corporation | -100 |
Customer Loyalty is a strong indicator of whether or not a customer will choose a brand repeatedly over a competitor that offers similar products/services.
72% of Incyte users/customers answered "Yes" when asked: "Would you consider yourself a loyal user/customer?"
Sign Up to see the full customer demographics data and the people that answered "Yes" when asked "Would you consider yourself a loyal user/customer?"
Compared to its competitors, Incyte's Customer Loyalty score is rated right above National Research Corporation, and is preceded by Biogen.
| COMPANY | Customer Loyalty Score | |
|---|---|---|
![]() | Karyopharm Therapeutics | 100% |
![]() | MyoKardia | 100% |
![]() | Biogen | 75% |
![]() | Incyte | 72% |
![]() | National Research Corporation | 10% |
![]() | Pharmacyclics | N/A |
![]() | ARIAD Pharmaceuticals | N/A |
![]() | Reata Pharmaceuticals | N/A |
Incyte has an overall Product Quality score of 3.9 out of 5 stars rated by its users and customers.
Sign Up to unlock Incyte's overall Product Quality score rated by its users and customers.
Incyte’s product quality score is a 3.9 out of 5 as rated by its users and customers.
Compared to its competitors, Incyte's Product Quality score is rated right above Pharmacyclics, and is preceded by MyoKardia.
| COMPANY | Product Quality Score | |
|---|---|---|
![]() | Karyopharm Therapeutics | 5/5 |
![]() | Biogen | 4/5 |
![]() | MyoKardia | 4/5 |
![]() | Incyte | 3.9/5 |
![]() | Pharmacyclics | 1.5/5 |
![]() | National Research Corporation | 1.5/5 |
![]() | ARIAD Pharmaceuticals | N/A |
![]() | Reata Pharmaceuticals | N/A |
Incyte has a value for money and ROI score of 3.9 out of 5 stars rated by its users and customers.
Sign Up to unlock Incyte's overall ROI score rated by its users and customers.
Compared to its competitors, Incyte's ROI score is rated right above Biogen, and is preceded by MyoKardia.
| COMPANY | Pricing Score | |
|---|---|---|
![]() | Karyopharm Therapeutics | 5/5 |
![]() | MyoKardia | 4/5 |
![]() | Incyte | 3.9/5 |
![]() | Biogen | 3.8/5 |
![]() | National Research Corporation | 1.5/5 |
![]() | Pharmacyclics | N/A |
![]() | ARIAD Pharmaceuticals | N/A |
![]() | Reata Pharmaceuticals | N/A |
Incyte has an overall Customer Satisfaction score of 86 rated by its users and customers.
Sign Up to see the full customer demographics data and the people that answered "How would you rate your overall satisfaction with the service you received?"
Customer Satisfaction Score (also known as CSAT), is a metric used to quantify how satisfied customers are with a company or brand’s products and services. The Customer Satisfaction Score is based on customers response to the question: “How would you rate your overall satisfaction with the service you received?” The score is calculated using the formula: (The total number answer of “Very Satisfied” and “Satisfied”) ÷ (The total response) x100, and it is generally displayed in percentages. Some of the main benefits of the CSAT for businesses are tracking retention, identifying happy customers and growing relationships, and gaining repeat business to build a sustainable brand.
Compared to its competitors, Incyte's Customer Satisfaction score is rated right above Biogen.
| COMPANY | Customer Satisfaction (CSAT) Score | |
|---|---|---|
![]() | Incyte | 86% |
![]() | Biogen | 78% |
![]() | Karyopharm Therapeutics | 0% |
![]() | Pharmacyclics | 0% |
![]() | National Research Corporation | 0% |
![]() | ARIAD Pharmaceuticals | 0% |
![]() | MyoKardia | 0% |
![]() | Reata Pharmaceuticals | 0% |
Incyte has an overall Customer Service score of 3.8 out of 5 stars rated by its users and customers.
Sign Up to unlock Incyte's overall Customer Service score rated by its users and customers.
Experimental Station, Route 141 & Henry Clay Road, Building E336, Wilmington, DE 19880
http://www.incyte.com
(302)498-6700
Compared to its competitors, Incyte's Customer Service score is rated right above Biogen, and is preceded by MyoKardia.
| COMPANY | Customer Service Score | |
|---|---|---|
![]() | Karyopharm Therapeutics | 5/5 |
![]() | MyoKardia | 4/5 |
![]() | Incyte | 3.8/5 |
![]() | Biogen | 3.8/5 |
![]() | National Research Corporation | 1.5/5 |
![]() | Pharmacyclics | N/A |
![]() | ARIAD Pharmaceuticals | N/A |
![]() | Reata Pharmaceuticals | N/A |
Incyte has a 4.6/5 stars for its overall company culture rated by their employees

Incyte scored a 46 for Net Promoter Score and a 25 for Employee Net Promoter Score. NPS gauges how likely a customer of Incyte would recommend the brand to a friend. ENPS measures how likely Incyte employees would recommend working at Incyte to a friend.
| 69% | Promoters |
|---|---|
| 8% | Passive |
| 23% | Detractors |
| 60% | Promoters |
|---|---|
| 5% | Passive |
| 35% | Detractors |